JNJ—3Q14 US Xarelto sales now at annualized rate of $1.7B, +68% YoY (despite lack of approval in ACS): http://finance.yahoo.com/news/johnson-johnson-reports-2014-third-114500454.html Bayer books ex-US sales of Xarelto.